Voyager Therapeutics presented 3‑month GLP toxicology data for its tau‑silencing gene therapy VY1706 at the American Society of Gene & Cell Therapy (ASGCT) 2026 meeting in Boston, scheduled for May 11‑15. The announcement was made on April 27, 2026, marking the first preclinical safety assessment of the candidate.
The study confirms the safety profile of VY1706 and supports Voyager’s plan to file an IND in the second quarter of 2026 and begin first‑in‑human dosing in the second half of the year. The TRACER capsid platform enables intravenous delivery to the brain with high potency and low off‑target exposure, as demonstrated by non‑human primate data showing a 50‑73% reduction in tau mRNA across the cerebral cortex.
Voyager’s financial position remains strong, with $201.7 million in cash as of March 9, 2026 and a runway into 2028, giving the company the resources to advance VY1706 and other pipeline candidates. The GLP data reinforce Voyager’s strategy of leveraging the TRACER platform across multiple indications, positioning the company for future partnership and licensing opportunities.
Management emphasized the significance of the data. Todd Carter, Ph.D., Chief Scientific Officer, said, "As we prepare to advance our tau‑silencing gene therapy VY1706 into the clinic for Alzheimer’s disease in the second half of the year, we are assembling a comprehensive preclinical data package that consistently demonstrates a compelling pharmacology and safety profile, and we look forward to sharing the latest data at ASGCT." He added, "Even as we prepare to advance the first gene therapy leveraging our novel, I.V.-delivered, brain‑targeted TRACER capsids into the clinic, the team continues to raise the bar with new innovations to expand beyond the CNS via muscular and neuromuscular targeting and to expand the eligible patient population via immune evasion."
The GLP toxicology milestone is a key de‑risking event for VY1706 and validates Voyager’s proprietary delivery platform, potentially accelerating the company’s path to clinical trials and future revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.